Indivior PLC - Asset Resilience Ratio
Indivior PLC (INDV) has an Asset Resilience Ratio of 0.07% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Indivior PLC (INDV) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Indivior PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see INDV total asset value.
Liquid Assets Composition Over Time
This chart breaks down Indivior PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read INDV liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.00 Million | 0.07% |
| Total Liquid Assets | GBX1.00 Million | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Indivior PLC maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Indivior PLC Industry Peers by Asset Resilience Ratio
Compare Indivior PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Piramal Pharma Limited
NSE:PPLPHARMA |
Drug Manufacturers - Specialty & Generic | 0.73% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Indivior PLC (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Indivior PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.08% | GBX1.00 Million ≈ $121.67 |
GBX1.32 Billion ≈ $160.48K |
-4.73pp |
| 2023-12-31 | 4.81% | GBX94.00 Million ≈ $11.44K |
GBX1.95 Billion ≈ $237.75K |
-1.92pp |
| 2022-12-31 | 6.73% | GBX119.00 Million ≈ $14.48K |
GBX1.77 Billion ≈ $215.24K |
-- |
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more